logo
Earnings To Watch: Pediatrix Medical Group (MD) Reports Q2 Results Tomorrow

Earnings To Watch: Pediatrix Medical Group (MD) Reports Q2 Results Tomorrow

Yahoo2 days ago
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) will be reporting earnings this Tuesday before market open. Here's what investors should know.
Pediatrix Medical Group beat analysts' revenue expectations by 1.6% last quarter, reporting revenues of $458.4 million, down 7.4% year on year. It was a very strong quarter for the company, with an impressive beat of analysts' same-store sales estimates and a solid beat of analysts' EPS estimates.
Is Pediatrix Medical Group a buy or sell going into earnings? Read our full analysis here, it's free.
This quarter, analysts are expecting Pediatrix Medical Group's revenue to decline 7.9% year on year to $464.4 million, a deceleration from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $0.42 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Pediatrix Medical Group has missed Wall Street's revenue estimates four times over the last two years.
Looking at Pediatrix Medical Group's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. The Ensign Group delivered year-on-year revenue growth of 18.5%, beating analysts' expectations by 0.7%, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. The Ensign Group traded up 8.7% following the results while CVS Health's stock price was unchanged.
Read our full analysis of The Ensign Group's results here and CVS Health's results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Pediatrix Medical Group is down 10.9% during the same time and is heading into earnings with an average analyst price target of $17.14 (compared to the current share price of $11.98).
Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mizuho Lifts Occidental (OXY) Price Target but Holds Neutral Rating
Mizuho Lifts Occidental (OXY) Price Target but Holds Neutral Rating

Yahoo

time4 minutes ago

  • Yahoo

Mizuho Lifts Occidental (OXY) Price Target but Holds Neutral Rating

Occidental Petroleum Corporation (NYSE:OXY) is one of the 12 Best American Energy Stocks to Buy Right Now. On July 14, Mizuho increased its price target for Occidental Petroleum Corporation (NYSE:OXY) from $58 to $65 and kept a Neutral rating on the stock. Mizuho expects the company to miss the consensus EBITDA estimates by about 8% in Q2 2025. This miss is attributed to the front-weighted capital spending, which significantly impacted free cash flow. Mizuho projects the free cash flow to be about 53% below street expectations. Oil derricks in the background with a few workers in the foreground, emphasizing the company's oil and gas production activities. According to Mizuho's review of Occidental Petroleum Corporation's (NYSE:OXY) recent 8-K filing, the company is seeing a slight impact on oil volumes in the Gulf of America, some strength in oil and liquids pricing, and weakness in US natural gas realizations. The firm attributed the expected miss in free cash flow primarily to heavy spending during the quarter, with about 55% of the 2025 budget allocated to the first half of the year. Based on the previous commentary by the company's management, Mizuho believes these headwinds are not expected to continue into the second half of 2025. Occidental Petroleum Corporation (NYSE:OXY) is an American multinational energy company with assets primarily in the United States, the Middle East, and North Africa. The company is one of the largest oil and gas producers in the US. While we acknowledge the potential of OXY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 12 Most Owned Stocks by Hedge Funds So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

MACOM (MTSI) Reports Earnings Tomorrow: What To Expect
MACOM (MTSI) Reports Earnings Tomorrow: What To Expect

Yahoo

time4 minutes ago

  • Yahoo

MACOM (MTSI) Reports Earnings Tomorrow: What To Expect

Network chips maker MACOM Technology Solutions (NASDAQ: MTSI) will be reporting earnings this Thursday before market hours. Here's what to look for. MACOM beat analysts' revenue expectations by 2.6% last quarter, reporting revenues of $235.9 million, up 30.2% year on year. It was a satisfactory quarter for the company, with a narrow beat of analysts' EPS estimates but an increase in its inventory levels. Is MACOM a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting MACOM's revenue to grow 31.1% year on year to $249.7 million, improving from the 28.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.90 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. MACOM has a history of exceeding Wall Street's expectations, beating revenue estimates every single time over the past two years by 0.9% on average. Looking at MACOM's peers in the analog semiconductors segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Skyworks Solutions delivered year-on-year revenue growth of 6.6%, beating analysts' expectations by 2.6%, and Impinj reported a revenue decline of 4.5%, topping estimates by 4.3%. Impinj traded up 26.2% following the results. Read our full analysis of Skyworks Solutions's results here and Impinj's results here. Investors in the analog semiconductors segment have had steady hands going into earnings, with share prices flat over the last month. MACOM's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $147.29 (compared to the current share price of $137.75). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

UBS Raises ConocoPhillips (COP) Price Target, Keeps Buy Rating
UBS Raises ConocoPhillips (COP) Price Target, Keeps Buy Rating

Yahoo

time4 minutes ago

  • Yahoo

UBS Raises ConocoPhillips (COP) Price Target, Keeps Buy Rating

ConocoPhillips (NYSE:COP) is one of the 12 Best American Energy Stocks to Buy Right Now. On July 11, UBS increased its price target for ConocoPhillips (NYSE:COP) from $111 to $115 while keeping a Buy rating. UBS noted that even though ConocoPhillips (NYSE:COP) delivered a positive operational update with its Q1 2025 results, the stock performance was hindered because of concerns about the company's capital return program. An underground network of pipelines transporting oil through an expansive terrain. The firm believes that if ConocoPhillips (NYSE:COP) has another strong quarter, it could improve investor confidence. UBS pointed out that 'this bandaid now ripped off' regarding capital return concerns. UBS also expects ConocoPhillips (NYSE:COP) to see an improvement in free cash flow as long-cycle spending starts to decrease in the second half of 2025. ConocoPhillips (NYSE:COP) is an American energy company that ranks among the world's largest independent oil and gas exploration and production companies based on production and proved reserves. While we acknowledge the potential of COP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 12 Most Owned Stocks by Hedge Funds So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store